March 2020 FDA Recall Drug by Fresenius Medical Care Holdings, Inc.
D-1064-2020 - CGMP Deviation
This Class II drug recall was voluntarily initiated by Fresenius Medical Care Holdings, Inc. on March 5, 2020 for the product Drug. The FDA reported the reason for recall as cgmp deviation. The product was distributed in Product was distributed throughout the United States. and the recall is currently terminated.
Recall Number: D-1064-2020
CGMP Deviation: Chemical indicators were not positioned properly during sterilization process.
03-05-2020
03-25-2020
32,592 bags
Recall Profile & Regulatory Data
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
Fresenius Medical Care Holdings, Inc.
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
Product was distributed throughout the United States.
02-03-2023
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
Sodium Chloride 0.9% Injection, USP, 1000 mL bags, Rx only, Manufactured by: Fresenius Medical Care North America, Waltham, MA 02451
Batch or Lot Expiration Information
Lot# : 19EG02012, 19EG02019, Exp. Date 05/2020; 19DG02050, Exp. Date 04/2020